Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16879605 | 0.91 | GLS (1.00) | GLS | |
| SCHEMBL16879584 | 0.91 | GLS (1.00) | GLS | |
| SCHEMBL16879377 | 0.89 | GLS (0.81) | GLS | |
| SCHEMBL16879614 | 0.88 | GLS (0.84) | GLS | |
| SCHEMBL16879361 | 0.87 | GLS (0.78) | GLS | |
| Telaglenastat SCHEMBL30278811 | 0.87 | GLS (1.00) | GLS | |
| Telaglenastat SCHEMBL29529521 | 0.87 | GLS (1.00) | GLS | |
| Telaglenastat SCHEMBL14987180 | 0.87 | GLS (1.00) | GLS | |
| Telaglenastat SCHEMBL17498257 | 0.86 | GLS (0.98) | GLS | |
| Telaglenastat SCHEMBL17498265 | 0.86 | GLS (0.98) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112920180-A | Glutaminase inhibitors | 理森制药股份公司 | 2021-06-08 | — | — | CN | claimed |
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | claimed |
| CN-112920180-A | Glutaminase inhibitors | 理森制药股份公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-105960405-B | Glutaminase inhibitors | 理森制药股份公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3092235-A2 | NOVEL INHIBITORS OF GLUTAMINASE | Rhizen Pharmaceuticals S.A. (CH) | 2016-11-16 | — | — | EP | disclosed |
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| WO-2015101958-A2 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS SA (CH) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015101958-A2 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS SA (CH) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.